HP
CLVS

Harbourvest Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Harbourvest Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-21,437
Closed -$2.01M – 29
2017
Q2 		$2.01M Buy
+21,437
New +$1.31M 0.86% 9
2015
Q4 		– Sell
-35,618
Closed -$3.27M – 29
2015
Q3 		$3.27M Buy
35,618
+14,518
+69% +$1.26M 1.45% 8
2015
Q2 		$1.85M Buy
+21,100
New +$1.81M 0.85% 10
2015
Q1 		– Sell
-51,037
Closed -$2.86M – 25
2014
Q4 		$2.86M Buy
+51,037
New +$2.68M 1.5% 9

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harbourvest Partners's CLVS Position: Q3 2017 in Review

Harbourvest Partners sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 21,437 shares — an estimated $2.01M sold.

Harbourvest Partners first reported a position in CLVS in Q4 2014 and held it in 4 quarters. The position peaked at $3.27M in Q3 2015. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Harbourvest Partners reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Harbourvest Partners sold 21,437 Clovis Oncology, Inc. shares in Q3 2017, an estimated $2.01M.
  • Harbourvest Partners first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 4 quarters.
  • Harbourvest Partners's Clovis Oncology, Inc. position peaked at $3.27M in Q3 2015.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Harbourvest Partners's 13F filing for Q3 2017, filed 14 Nov 2017.